Abbott Laboratories Corporation

Abbvie Inc.

Lyvgen Biopharma Holdings Limited

Abbvie Biotherapeutics Inc.

Lyvgen Biopharma Co., Ltd.

Lyvgen Biopharma (suzhou) Co., Ltd.

Jieyi Wang

George S Sheppard

Gary T Wang

Robert A Mantei

Megumi Kawai

Randy Bell

Scott A Erickson

Steve D Fidanze

Richard A Craig

Edward B Reilly

Nwe Y BaMaung

Yi Wu

Bryan K Sorensen

Richard F Clark

Jack Henkin

Mark Anderson

Nwe Y Ba-maung

Chung-Ming Hsieh

Jyoti R Patel

Xenia Beebe Searle

Debra Chao

Robert Dale Hubbard

Linda M Lynch

Archana Thakur

Qian Zhang

Charles W Hutchins

Anil Vasudevan

Tariq Ghayur

Daniel E Afar

David M Barnes

Kenton L Longenecker

Christian B Allan

Lawrence Kolaczkowski

Yaolin Wang

Douglas M Kalvin

Donald J Davidson

Robert Hubbard

Yoshiko Akamatsu

Gillian A Kingsbury

Susan Elizabeth Morgan-Lappe

Yingchun Li

William Sanders

Jason S Tedrow

Louie Naumovski

Andrew C Phillips

Junjian Liu

Earl J Gubbins

Hua Ying

Enrico L Digiammarino

Liqun Dong

Fabio Palazzo

Suzanne M Norvell

Kenneth M Comess

Ki H Kim

Chang Hoon Park

Russell A Judge

David C Park

David A Egan

Fan Yang

Nwe Ba-Maung

Nwe Bamaung

Randy L Bell

Mark G Anderson

Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and FcγRIIB.

Therapeutic agents and methods for enhancing immune responses in tumor microenvironment

Disclosed herein are agnostic anti-CD40 antibodies and methods of using such for eliciting CD40 signaling, thereby enhancing immune responses, such as dendritic cell functions. The antibodies disclosed herein may be used to treat diseases, such as cancer and immune disorders.

Anti-CD40 antibodies and uses thereof

Disclosed herein are agonistic anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.

Anti-CD137 antibodies and uses thereof

Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.

Humanized anti-CD137 antibodies and uses thereof

The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fc&#x3b3; receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.

Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof

Anti-PD-1 antibodies and uses thereof in treating diseases associated with the PD-1 signaling, such as cancer, infectious diseases such as viral infection or immune related diseases.

Anti-PD-1 antibodies and therapeutic uses thereof

The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Anti-4-1BB antibodies and their uses

The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Anti-cMet antibody drug conjugates and methods for their use

The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Prolactin receptor binding proteins and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G, L, R, R, n, p, Ar, and Arare defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.

Pyrimidine inhibitors of kinase activity

Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L, R, R, R, R, R, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G, R, R, R, R, n, p, q, Ar, and Arare defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.

Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Protein kinase inhibitors

Growing community of inventors

Lake Bluff, IL, United States of America

Jieyi Wang